Evidence map›Paper›PMID 25171061›Full record

ArticlePloS one2014

TIMP-3 expression associates with malignant behaviors and predicts favorable survival in HCC.

Xuefeng Gu, Maoying Fu, Yuqin Ding, Huihui Ni, Wei Zhang, Yanfang Zhu, Xiaojun Tang, Lin Xiong, Jiang Li, Liang Qiu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Associations ofInternational journal of molecular sciences · 2020
    Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. TIMP-3 as a therapeutic target for cancer.Therapeutic advances in medical oncology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Xuefeng GuDepartment of Infectious Diseases, The First People's Hospital of Kunshan Affiliated with Jiangsu University, Suzhou, China.
Maoying FuDepartment of Infectious Diseases, The First People's Hospital of Kunshan Affiliated with Jiangsu University, Suzhou, China.
Yuqin DingDepartment of Infectious Diseases, The First People's Hospital of Kunshan Affiliated with Jiangsu University, Suzhou, China.
Huihui NiDepartment of Infectious Diseases, The First People's Hospital of Kunshan Affiliated with Jiangsu University, Suzhou, China.
Wei ZhangDepartment of Infectious Diseases, The First People's Hospital of Kunshan Affiliated with Jiangsu University, Suzhou, China.
Yanfang ZhuDepartment of Infectious Diseases, The First People's Hospital of Kunshan Affiliated with Jiangsu University, Suzhou, China.
Xiaojun TangThe Key Laboratory of Cancer Biomarkers, Prevention & Treatment Cancer Center and The Key Laboratory of Antibody Technique of Ministry of Health, Nanjing Medical University, Nanjing, China.
Lin XiongDepartment of Pathology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jiang LiDepartment of Pathology, Jiangsu Province Geriatric Institute, Nanjing, China.
Liang QiuDepartment of Pathology, Jiangsu Province Geriatric Institute, Nanjing, China.
Jiaren XuDepartment of Hematology and Oncology, Jiangsu Provincial Hospital, Nanjing, China.
Jin ZhuThe Key Laboratory of Cancer Biomarkers, Prevention & Treatment Cancer Center and The Key Laboratory of Antibody Technique of Ministry of Health, Nanjing Medical University, Nanjing, China; Huadong Medical Institute of Biotechniques, Nanjing, China.
First People's Hospital of Kunshan · CNHuadong Hospital · CNJiangsu Provincial Hospital of Traditional Chinese Medicine · CNJiangsu University · CNNanjing Medical University · CNSecond Affiliated Hospital of Nanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tissue inhibitors of metalloproteinases (TIMPs) are proteins that specifically inhibit the proteolytic activity of the matrix metalloproteinases (MMPs). TIMP-3, the only member of the TIMPs that can tightly bind to the extracellular matrix, has been identified as a unique tumor suppressor that demonstrates the ability to inhibit tumor angiogenesis, invasion, and metastasis. This study aimed to detect the expression of TIMP-3 in hepatocellular carcinoma (HCC) and investigate the association between TIMP-3 expression and its clinicopathological significance in HCC patients. In the current study, reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting of HCC cell lines and one-step quantitative reverse transcription PCR (qPCR) and immunohistochemistry (IHC) analyses in HCC tissues were performed, to characterize the TIMP-3 expression. Kaplan-Meier survival and Cox regression analyses were utilized to evaluate the prognosis of 101 HCC patients. The results showed that the expression of TIMP-3 in HCC was significantly decreased relative to that of non-cancerous cells and tissues. Furthermore, the TIMP-3 expression was statistically associated with malignant behaviors of HCC, including portal vein invasion (p = 0.036) and lymph node metastasis (p = 0.030). Cox regression analysis revealed that TIMP-3 expression was an independent prognostic factor for disease-free survival (p = 0.039) and overall survival (p = 0.049). These data indicate that TIMP-3 expression is a valuable prognostic biomarker for HCC and that TIMP-3 expression suggests a favorable prognosis for HCC patients.

Indexed as

AdultAgedCarcinoma, HepatocellularCell Line, TumorDisease-Free SurvivalFemaleHumansLiver NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm InvasivenessPrognosisSurvival RateTissue Inhibitor of Metalloproteinase-3TIMP3 protein, humanTissue Inhibitor of Metalloproteinase-3

Identifiers

PMID25171061
PMCPMC4149530
OpenAlexW2088141041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.